Clinical Trials Browser

Lung Neoplasms

Neoplasms, Neuroblastoma

Neuroblastoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis, Sarcoma

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

Carcinoma, Non-Small-Cell Lung

Carcinoma, Carcinoma, Pancreatic Ductal

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

ALK-positive NSCLC

Carcinoma, Non-Small-Cell Lung

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lymphoma, B-Cell, Hematologic Neoplasms

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Carcinoma, Non-Small-Cell Lung, Neoplasms

Brain Neoplasms, Glioblastoma

Carcinoma, Non-Small-Cell Lung

Granuloma, Plasma Cell, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Large-Cell, Anaplastic

Carcinoma, Non-Small-Cell Lung

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Noonan Syndrome 6, Melanoma

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Lymphoma, Large-Cell, Anaplastic

Thyroid Carcinoma, Anaplastic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Hematologic Neoplasms

Clinical Trials

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

NEPENTHE

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

PEDS-PLAN

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

MULTISARC

Managed Access Programs for LDK378, Ceritinib

DELINOR

Using Tumor Models to Determine Treatments

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

IMPRESS-N

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Antineoplastic Drugs in Elderly Patients

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

SIGNATURE

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Ascend-7

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

Ceritinib Rare Indications Study in ALK+ Tumors

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies